A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

NCT04971733 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: E2814

Sponsor

Eisai Inc.